These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38238616)

  • 1. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19
    Marin D; Li Y; Basar R; Rafei H; Daher M; Dou J; Mohanty V; Dede M; Nieto Y; Uprety N; Acharya S; Liu E; Wilson J; Banerjee P; Macapinlac HA; Ganesh C; Thall PF; Bassett R; Ammari M; Rao S; Cao K; Shanley M; Kaplan M; Hosing C; Kebriaei P; Nastoupil LJ; Flowers CR; Moseley SM; Lin P; Ang S; Popat UR; Qazilbash MH; Champlin RE; Chen K; Shpall EJ; Rezvani K
    Nat Med; 2024 Mar; 30(3):772-784. PubMed ID: 38238616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
    Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
    N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
    Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
    Guo S; Lei W; Jin X; Liu H; Wang JQ; Deng W; Qian W
    Blood Adv; 2024 Jun; 8(11):2635-2645. PubMed ID: 38564778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies.
    He B; Mai Q; Pang Y; Deng S; He Y; Xue R; Xu N; Zhou H; Liu X; Xuan L; Li C; Liu Q
    Front Immunol; 2023; 14():1130442. PubMed ID: 37207215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL.
    Song F; Hu Y; Zhang Y; Zhang M; Yang T; Wu W; Huang S; Xu H; Chang AH; Huang H; Wei G
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
    Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect
    Silvestre RN; Eitler J; de Azevedo JTC; Tirapelle MC; Fantacini DMC; de Souza LEB; Swiech K; Covas DT; Calado RT; Montero PO; Malmegrim KCR; Figueiredo ML; Tonn T; Picanço-Castro V
    Front Immunol; 2023; 14():1226518. PubMed ID: 37818365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
    [No Abstract]   [Full Text] [Related]  

  • 14. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].
    Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
    Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
    Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
    Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
    J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.